Modeling cost-effectiveness analysis of treatment sequencing

Cristina del Campo; Jiaru Bai; L. Robin Keller

doi:10.1016/j.seps.2025.102210

Modeling cost-effectiveness analysis of treatment sequencing

Cristina del Campo
, Jiaru Bai
, L. Robin Keller

Dean's Office, College of Business

Complutense University
University of California at Irvine

Research output: Contribution to journal › Article › peer-review

Abstract

In clinical practice, patients with cancer often undergo treatment with a sequence of drugs, usually because of diminishing effectiveness over time or resistance development. However, few cost-effectiveness analyses have included that fact in their model. This paper aims at closing that gap by presenting a model that reflects the possibility of the patient switching from one therapeutic agent to another one throughout the long-term duration of his/her life.

Original language	English
Article number	102210
Journal	Socio-Economic Planning Sciences
Volume	99
DOIs	https://doi.org/10.1016/j.seps.2025.102210
State	Published - Jun 2025

Keywords

Cost-effectiveness analysis
Decision analysis
Markov model
Multiple lines of treatment
Treatment sequencing

Access to Document

10.1016/j.seps.2025.102210

Cite this

@article{ffd5755cebc941d8833aa3bd6d31cbd9,

title = "Modeling cost-effectiveness analysis of treatment sequencing",

abstract = "In clinical practice, patients with cancer often undergo treatment with a sequence of drugs, usually because of diminishing effectiveness over time or resistance development. However, few cost-effectiveness analyses have included that fact in their model. This paper aims at closing that gap by presenting a model that reflects the possibility of the patient switching from one therapeutic agent to another one throughout the long-term duration of his/her life.",

keywords = "Cost-effectiveness analysis, Decision analysis, Markov model, Multiple lines of treatment, Treatment sequencing",

author = "\{del Campo\}, Cristina and Jiaru Bai and Keller, \{L. Robin\}",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Ltd",

year = "2025",

month = jun,

doi = "10.1016/j.seps.2025.102210",

language = "English",

volume = "99",

journal = "Socio-Economic Planning Sciences",

issn = "0038-0121",

}

TY - JOUR

T1 - Modeling cost-effectiveness analysis of treatment sequencing

AU - del Campo, Cristina

AU - Bai, Jiaru

AU - Keller, L. Robin

PY - 2025/6

Y1 - 2025/6

N2 - In clinical practice, patients with cancer often undergo treatment with a sequence of drugs, usually because of diminishing effectiveness over time or resistance development. However, few cost-effectiveness analyses have included that fact in their model. This paper aims at closing that gap by presenting a model that reflects the possibility of the patient switching from one therapeutic agent to another one throughout the long-term duration of his/her life.

AB - In clinical practice, patients with cancer often undergo treatment with a sequence of drugs, usually because of diminishing effectiveness over time or resistance development. However, few cost-effectiveness analyses have included that fact in their model. This paper aims at closing that gap by presenting a model that reflects the possibility of the patient switching from one therapeutic agent to another one throughout the long-term duration of his/her life.

KW - Cost-effectiveness analysis

KW - Decision analysis

KW - Markov model

KW - Multiple lines of treatment

KW - Treatment sequencing

UR - https://www.scopus.com/pages/publications/105001820396

U2 - 10.1016/j.seps.2025.102210

DO - 10.1016/j.seps.2025.102210

M3 - Article

AN - SCOPUS:105001820396

SN - 0038-0121

VL - 99

JO - Socio-Economic Planning Sciences

JF - Socio-Economic Planning Sciences

M1 - 102210

ER -

Modeling cost-effectiveness analysis of treatment sequencing

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this